Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Rigosertib Dosing Schedules in MDS
NCT02075034Phase 1Withdrawn
- Sponsor
- Traws Pharma, Inc.
- Start
- May 2014
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rigosertib in myelodysplastic syndrome (MDS) (3 arms), sponsored by Traws Pharma, Inc. Primary endpoints: Micrograms of rigosertib per milliliter of plasma, Micrograms of rigosertib per milliliter of urine and 1 more. Planned start May 2014; status: withdrawn.
02
Drugs
rigosertib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02075034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02075034.